An in situ injectable thermosensitive response hydroxypropyl chitosan composite hydrogel for lacrimal embolism and its preparation method and application

Abstract

The invention discloses an in-situ injectable temperature-sensitive response hydroxypropyl chitosan composite hydrogel for lacrimal duct embolism, a preparation method and application thereof, and belongs to the technical field of medical products. The composite hydrogel of the present invention is a liquid sol at room temperature and has fluidity, and the sol can be placed into the lacrimal duct of the human eye by punctum injection. Utilizing the gel phase transition characteristic of the sol that is sensitive to body temperature, the in-situ gel embolization of the sol in the lacrimal duct is realized, and a small amount of tear fluid secreted by the affected eye is retained in the orbit, so as to achieve the purpose of keeping the ocular surface moist for a long time. Using the body temperature responsiveness of hydroxypropyl chitosan and sodium glycerophosphate complex, and adding alginate and calcium chloride to adjust its mechanical properties, sol-gel phase transition time, mechanical strength, etc., the operation is simple, The reaction conditions are mild, the cost is low, the biocompatibility is good, the trauma is small, and the lacrimal duct of any shape and size can be filled, and it has a good relief effect on patients with dry eye.

Description

technical field [0001] The invention belongs to the technical field of medical products, and relates to an in-situ injectable temperature-sensitive responsive hydroxypropyl chitosan composite hydrogel for lacrimal duct embolism, a preparation method and application thereof. Background technique [0002] Dry eye disease is an ocular disease caused by a variety of causes such as congenital lacrimal gland hypoplasia, trachoma, and corneal sclerosis, resulting in decreased tear film stability and abnormal tear quality or quantity. The etiology is more complex, related to the body's immunity, hormones and various growth factors, and generally requires long-term treatment. The essence of the disease is the reduction of the number and density of goblet cells in the tear film, which causes changes in the quality or quantity of tear secretion. The clinical symptoms are mainly dry eyes, itching, etc. The long-term accumulation of symptoms will cause deep lesions in the patient's corn...

AI Technical Summary

Problems solved by technology

At present, the lacrimal duct embolization products used in the clinical treatment of dry eye disease in my country are all dependent on imports, which are expensive (1000-3000 yuan), and the cost of materials accounts for more than 80-90% of the operation cost, which greatly increases the economic burden of patients

In addition, the more important reason is that the imported lacrimal plug products designed based on European and American populations cannot fully adapt to the eye anatomical characteristics of Asian populations. In clinical applications, there are often problems of embolism shifting or falling off, resulting in surgical failure.

Images